LOS ANGELES and HONG KONG, May 31, 2011 /PRNewswire-Asia/ -- ArtificialLife, Inc., (OTC BB: ALIFE), a leading provider of award-winning mobile technology and applications, announced today their upcoming product Opus-Mô Health: Dermatitis (short form: Opus-M Health: Dt), a healthcare app specifically geared
Dermatitis is any condition characterized by inflammation of the skin and affects both males and females equally. In the United States, 1 in 30 (or approximately 8 million) people are affected.* While there are various types of dermatitis, all share some common symptoms such as itching, lesions, swelling, and occasional weeping of fluids from the skin. †All of these symptoms may be monitored and recorded using Artificial Life (ALIFE)'s Opus-Mô Health: Dermatitis app.
Opus-M Health: Dermatitis includes a slideshow function for recording pictures of skin conditions and allows for PDF sharing of records via iTunes. Using Opus-M Health: Dermatitis, patients are able to record their skin conditions with more than 10 attribute options such as lesions, distribution, surface texture, and more. In addition, the app contains a body mapping feature to provide a clear and comprehensive indication of affected areas throughout the body. Overall, the Opus-M Health: Dermatitis app allows users to effectively keep track of their dermatitis-related body conditions and easily share this information with their doctors and caregivers. †
Features of Opus-M Health: Dermatitis include:
As with all applications in the Opus-M Health family, Opus-M Health: Dermatitis will leverage Artificial Life's Opus-M platform for end-consumers, healthcare providers, and healthcare businesses. The app is scheduled to launch on the Apple App Store in Q2 2011 pending approval and will be available later for Android and Windows Phone 7.
Opus-M Health: Dermatitis follows the Company's successful launch of GluCoMoô, its diabetes monitoring app, and Opus-M Health: Neurodermatitis. Artificial Life's Opus-M Health platform will continue to expand and feature more healthcare apps such as the previously announced upcoming apps: Opus-M Health: Neurodermatitis Kids Edition, an expansion of the Opus-M healthcare skin app developed specifically for children affected by neurodermatitis; and Opus-M Health: HIV/AIDS, a healthcare app that is used for the monitoring of HIV/AIDS. More information about apps by Artificial Life can be found at www.botme.com and www.artificial-life.com.
"We are delighted to introduce Opus-M Health: Dermatitis into the Opus-M Health family. With its new features such as the body mapping function, this application shows Artificial Life's constant efforts to enhance the capabilities of its products to better meet the needs of users," said Eberhard Schoneburg, CEO of Artificial Life, Inc.
*Source: 1. "Prevalence and Incidence of Dermatitis," CureResearch.com, May 31, 2011. http://www.cureresearch.com/d/dermatitis/prevalence_printer.htm
App Store is a service mark of Apple Inc.
Android is a trademark of Google Inc. Use of this trademark is subject to Google Permissions.
Windows is a registered trademark of Microsoft Corporation in the United States and/or other countries.
About Artificial Life, Inc.
Artificial Life, Inc. has been a pioneer in artificial intelligence and mobile technology since its inception in Boston in 1994. We are a public US corporation (OTC BB: ALIFE) with listing on the Frankfurt Stock Exchange (Frankfurt: AIF.F; Xetra: AIF.DE) and headquarters and production center in Hong Kong. We have additional offices in Berlin, Germany (EMEA headquarters), Tokyo, Japan, and Santa Monica, USA. Currently our main business areas are: high quality (3D) interactive (massively multiplayer) mobile games, mobile participation television, mobile business applications, our powerful mobile commerce technology platform OPUS-Mô and our green IT solutions provided by Green Cortex, Inc. We have won many industry awards for our outstanding technology and products.
Facebook: http://www.botme.com/ref/alife-fb Twitter: http://twitter.com/alifegames MySpace: http://www.myspace.com/artificial_life_inc YouTube: http://www.youtube.com/user/alifegames
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements include, without limitation, statements regarding our future results of operations, financial condition and business prospects. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "continue" or the negative of these terms or other comparable terminology. Although such statements are based on our own information and information from other sources we believe to be reliable, you should not place undue reliance on them. These statements involve risks and uncertainties, and actual market trends or our actual results of operations, financial condition or business prospects may differ materially from those expressed or implied in these forward looking statements for a variety of reasons. Potential risks and uncertainties include, but are not limited to, our ability to obtain additional funding to operate and grow our business; the unproven potential of our mobile gaming business model; changing consumer preferences and uncertainty of market acceptance of our products; timely adoption and availability of 3G mobile technology; market acceptance for use of mobile handheld devices to play the interactive games; unpredictable mobile game development schedules; our reliance on a relatively small number of brands; our ability to license brands from others; our dependence upon resellers and telecommunication carriers and operators to distribute our products; our ability to successfully develop, introduce, and sell new or enhanced products in a timely manner; and the timing of new product announcements or introductions by us or by our competitors. For additional discussion of these risks and uncertainties and other factors, please see the documents we file from time to time with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB filed on March 16, 2010. We assume no obligation to update any forward-looking statements, which apply only as of the date of this press release.
For more information on ARTIFICIAL LIFE, INC., please contact:
Artificial Life IR and PR Contact: Adeline Law Tel: +852-3102-2800 email@example.com
SOURCE Artificial Life, Inc.
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All